| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.12 | 0.04 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.24 | 0.04 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.085 | 0.04 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.082 | 0.05 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.05 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.05 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.05 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.06 |